Replies to post #139061 on Biotech Values

[biomaven0]

showed superiority to GSK's existing twice-daily drug Advair in one trial for chronic lung disease, but not another

Showing superiority to a good drug is always going to be very tough.

Peter

[DewDiligence]

GSK increases equity stake in THRX from 18% to 26% in return for $213M in cash:

http://finance.yahoo.com/news/glaxosmithkline-increase-ownership-theravance-113332956.html